About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« No Discovery in New Rules Case | Main | Astellas to Acquire Agensys,Inc. »

November 27, 2007

GSK to Acquire Reliant Pharmaceuticals

    By Sherri Oslick --

Glaxosmithkline GlaxoSmithKline of London, UK and Philadelphia, PA and Reliant Pharmaceuticals of Liberty Corner, NJ have announced an agreement under which GSK will acquire Reliant for $1.65 billion in cash.  Reliant is a privately held pharmaceutical company focused on cardiovascular therapeutics.

Reliant_pharm Reliant's therapeutic portfolio has been developed through in-licensing and development of cardiovascular medicines.  Included in its portfolio is Lovaza (formerly Omacor®; omega-3-acid ethyl esters), which is used to treat adult patients with very high triglyceride levels, and which was launched in 2005 and is licensed (in the U.S. and Puerto Rico) from Pronova BioPharma ASA of Norway.  Lovaza will compliment GSK's primary cardiovascular therapeutic, Coreg CR® (carvedilol phosphate), which is used to treat heart failure and hypertension.

In addition to Lovaza, Reliant's portfolio includes DynaCirc CR® (isradipine) and InnoPran XL® (propanolol hydrochloride), both of which are used to treat hypertension, Rythmol® SR (propafenone hydrochloride), which is used to treat arrhythmia, and Axid® (nizatidine), which is used to treat ulcers  The acquisition is expected to be completed by the end of the year, pending FTC approval.

For additional information regarding GSK's acquisition of Reliant, please see:

Posted at 10:39 PM in Licensing |

Comments

The comments to this entry are closed.

May 2023

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31      

Categories

Archives

More...